818TiP A pivotal phase II, randomized, controlled, open-label, trial (MIZAR-003) to assess the efficacy and safety of GC101 TIL, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, for patients with advanced anti-PD-1 refractory melanoma in later-line therapy
Year: 2025
Type: article
Language: en
Topic: Cancer Immunotherapy and Biomarkers
Authors and affiliations:
raw_author_name: J. Gu
raw_affiliation_strings: Department of Melanoma and sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
raw_author_name: L. Si
raw_affiliation_strings: Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
raw_author_name: W. Zhang
raw_affiliation_strings: Medical Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China
raw_author_name: Y. Chen
raw_affiliation_strings: Department of Hepatobiliary-Pancreatic Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China
raw_author_name: J. Chen
raw_affiliation_strings: Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, China
raw_author_name: X. Zhang
raw_affiliation_strings: Department of Biological Therapy Center, Sun Yat-sen University Cancer Center, Guangzhou, China
raw_author_name: M. Fang
raw_affiliation_strings: Key Laboratory of Head and Neck Oncology Rare diseases/head and neck medicine, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China
raw_author_name: D. Zhu
raw_affiliation_strings: Rare Tumors Department, Shandong Cancer Hospital and Institute, Jinan, China
raw_author_name: Z. Zou
raw_affiliation_strings: The Comprehensive Cancer Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
raw_author_name: Z. Luo
raw_affiliation_strings: Medical Oncology Department, Fudan University Shanghai Cancer Center, Shanghai, China
raw_author_name: Q. Gao
raw_affiliation_strings: Department of Immunotherapy, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
raw_author_name: Z. Yuan
raw_affiliation_strings: Department of Bone and Soft Tissue Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
raw_author_name: D. Wu
raw_affiliation_strings: Cancer Centre, The First Hospital of Jilin University, Changchun, China
raw_author_name: J. Liu
raw_affiliation_strings: Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
raw_author_name: W. Ma
raw_affiliation_strings: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
raw_author_name: X. Pu
raw_affiliation_strings: Thoracic Medicine Department, Hunan Cancer Hospital, Changsha, China
raw_author_name: H. Feng
raw_affiliation_strings: Thoracic Oncology Department, Bethune Hospital, Taiyuan, China
raw_author_name: J. Liu
raw_affiliation_strings: Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
raw_author_name: H. Jin
raw_affiliation_strings: Department of Medicine, Shanghai Juncell Therapeutics Co., Ltd., Shanghai, China
raw_author_name: J. Guo
raw_affiliation_strings: Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China